诊断性测序中发现的DDX41变异患者的临床与基因组图谱
研究对5737例髓系恶性肿瘤患者行靶向二代测序,检出152种DDX41变异,并分析另一血液恶性肿瘤队列的全基因组转录组数据。MDS队列中108/2865(3.8%)、AML队列中106/2157(4.9%)携带胚系可能致病/致病(LP/P)变异,且DDX41 LP/P变异在AML和MDS中较骨髓增殖性肿瘤、B细胞肿瘤及急性淋巴细胞白血病明显富集。
要点
- MDS患者中DDX41胚系LP/P变异占3.8%(108/2865),AML中占4.9%(106/2157)。
- 体细胞DDX41变异与胚系DDX41变异在MDS和AML患者中高度相关。
- 研究建立统计方法将体细胞DDX41变异共现纳入胚系变异分类,可达非常强证据等级。
核心结论
- 研究建立了增强DDX41变异解读的框架,并强调评估所有类型基因组变异(包括同义变异和多外显子缺失)对全面检出可能临床相关DDX41变异的重要性。
研究设计与样本
- 对连续招募的髓系恶性肿瘤患者行靶向二代测序,覆盖DDX41及30个其他髓系恶性肿瘤常见突变基因。
- 对另一组涵盖多种血液恶性肿瘤的患者行全基因组转录组测序分析,以探究癌症易感基因谱。
- 共研究5737例髓系恶性肿瘤患者,检出152种不同的DDX41变异。
主要发现
- 检出多种新变异,包括经RNA测序证实影响剪接的同义变异。
- 体细胞DDX41变异与胚系DDX41变异在MDS和AML患者中高度相关。
- MDS队列中108/2865(3.8%)患者携带胚系LP/P变异,AML队列中106/2157(4.9%)。
- DDX41 LP/P变异在AML和MDS患者中较骨髓增殖性肿瘤、B细胞肿瘤及T或B细胞急性淋巴细胞白血病患者明显富集。
关键数值与推荐
- 依据美国医学遗传学与基因组学学会/分子病理学协会(ACMG/AMP)指南,将体细胞DDX41变异共现纳入胚系变异分类可达非常强证据等级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deleterious germ line variants in DDX41 are a common cause of genetic predisposition to hematologic malignancies, particularly myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). Targeted next-generation sequencing was performed in a large cohort of sequentially recruited patients with myeloid malignancy, covering DDX41 as well as 30 other genes frequently mutated in myeloid malignancy. Whole genome transcriptome sequencing data was analyzed on a separate cohort of patients with a range of hematologic malignancies to investigate the spectrum of cancer predisposition. Altogether, 5737 patients with myeloid malignancies were studied, with 152 different DDX41 variants detected. Multiple novel variants were detected, including synonymous variants affecting splicing as demonstrated by RNA-sequencing. The presence of a somatic DDX41 variant was highly associated with DDX41 germ line variants in patients with MDS and AML, and we developed a statistical approach to incorporate the co-occurrence of a somatic DDX41 variant into germ line variant classification at a very strong level (as per the American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines). Using this approach, the MDS cohort contained 108 of 2865 (3.8%) patients with germ line likely pathogenic/pathogenic (LP/P) variants, and the AML cohort 106 of 2157 (4.9%). DDX41 LP/P variants were markedly enriched in patients with AML and MDS compared with those in patients with myeloproliferative neoplasms, B-cell neoplasm, and T- or B-cell acute lymphoblastic leukemia. In summary, we have developed a framework to enhance DDX41 variant curation as well as highlighted the importance of assessment of all types of genomic variants (including synonymous and multiexon deletions) to fully detect the landscape of possible clinically relevant DDX41 variants.
引用
- Maierhofer A, Mehta N, Chisholm RA, et al. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing. Blood Adv. 2023. PMID: 37874914. doi:10.1182/bloodadvances.2023011389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。